

## SCIENTIFIC COORDINATORS

Filippo de Marinis

Silvia Novello

## FACULTY

Ilaria Attili

Alessandra Bearz

Chiara Bennati

Emilio Bria

Rita Chiari

Filippo de Marinis

Francesco Grossi

Federico Mereta

Michele Milella

Silvia Novello

Maria Vittoria Pacchiana Parravicini

Fabio Pagni

Giulia Pasello

Francesco Passiglia

Sara Pilotto

Arsela Prelaj

Maria Lucia Reale

Hector Jose' Soto-Parra

Milano

Aviano (PN)

Ravenna

Roma

Pesaro

Milano

Varese

Genova

Verona

Orbassano (TO)

Torino

Milano

Padova

Orbassano (TO)

Verona

Milano

Lecce

Catania

## CME CREDITS

Certificate awarding 6 CME credits for Biologists, Surgeons Specialized in Oncology, Radiology, Thoracic Surgery, Pathological Anatomy, Internal medicine, Radiotherapy

## EDUCATIONAL GOALS

guidelines - protocols - procedures

## CME PROVIDER AND ORGANIZING SECRETARIAT



OVER SRL  
info@overgroup.eu  
www.overgroup.eu

## UNCONDITIONAL SPONSORSHIP:

janssen  Oncology

PHARMACEUTICAL COMPANIES OF 

# EX<sub>20</sub>PLORE

The new way for EGFR NSCLC patients

12<sup>th</sup> May

2023

Verona

Crowne Plaza

Via Belgio, 16

SCIENTIFIC COORDINATORS

Filippo de Marinis

Silvia Novello

## RATIONAL

In Italy, lung cancer is the leading cause of death, accounting alone for around 20% of all cancer deaths and 28% of male deaths. Lung cancer is a biologically heterogeneous disease, therefore understanding its biology and the clinical behavior associated with the disease stands as crucial for the development of effective therapies. A better understanding of tumor biology has enabled the development of targeted therapies that brought light to the era of personalized medicine.

Over the past 20 years treatment has evolved from the empirical use of cytotoxic therapies towards effective and better tolerated regimens targeting specific molecular subtypes. Platinum-based chemotherapies have been standard therapies for patients with non-small cell lung cancer (NSCLC) for many years. Treatment is recently shifting from the empirical use of cytotoxic therapy towards a more personalized therapy, using targeted therapies or inhibitors of the immune checkpoints, with patients treated according to the genetic alterations of the tumor and the immune susceptibility status of the disease defined on the basis of PD-L1.

The current clinical approach to lung cancer cannot therefore disregard an in-depth knowledge of the natural history and biological mechanisms that underlie the functioning of modern targeted therapies and immunological therapies.

## MAY 12<sup>th</sup> SCIENTIFIC PROGRAMME

9.15  
Introduction to Congress Work  
**F. de Marinis, S. Novello**

9.25  
Oncogene addicted non small cell lung cancer  
**S. Novello**

### Session 1

Moderator: **S. Novello**

09.45  
1 - EGFR Exon 20 insertion: a new therapeutic target  
**C. Bennati**

10.05  
2 - Molecular portrait and testing of EGFR exon 20 insertions **F. Pagni**

10.20  
Discussion

10.30  
1 - The evolving scenario of first-line treatment of patients di EGFR mutations **F. Passiglia**

10.50  
2 - Overcoming osimertinib resistance in EGFR-mutant lung cancer **S. Pilotto**

11.05  
Discussion

11.15 - 11.25  
Coffee Break

## Session 2

Moderator: **F. de Marinis**

11.25  
**Interactive round table 1**  
Topic: managing EGFR exon 20 insertions in clinical setting: from diagnosis to treatment  
Case Study Presentation **I. Attili**

Discussants: **R. Chiari, F. Grossi, F. Pagni**

12.15  
**Interactive round table 2**  
Topic: the management of patients with common EGFR mutations: first line and resistance  
Case Study Presentation **M. L. Reale**

Discussants: **M. Milella, G. Pasello, A. Prelaj, H. J. Soto-Parra,**

13.05  
Take home message **F. de Marinis**

13.15 - 14.15  
Lunch

## Session 3

**Motivational Session**

14.15  
Doctor-patient communication (interaction with the audience)  
**M.V. Pacchiana Parravicini**

*-Innovation*  
*-Precision medicine*  
*-Patient identification*  
*-Paradigm shift*

15.15  
**“TED STYLE” SESSION** G. RAPETTI in arte **MOGOL**

15.30  
Moderated Talk show Supported by a Reporter  
Reporter: **F. Mereta**

Discussants: **A. Bearz, E. Bria**

*-Beyond your routine*  
*-Challenge your limits*  
*-The importance of change*

16.15 - 16.30  
Final Remarks

# EX<sub>20</sub>PLORE

The new way for EGFR NSCLC patients